Τίτλος:
Cisplatin-etoposide alternating with topotecan in patients with
extensive stage small cell lung cancer (SCLC) - A multicenter phase II
study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Purpose: In order to investigate the feasibility of a potentially
non-cross resistant drug regimen, we alternated cycles of
cisplatin-etoposide with topotecan as front-line treatment in patients
with extensive stage small cell lung cancer (SCLC). Patients and
Methods: Thirty-six previously untreated patients with extensive stage
SCLC received cisplatin 75 mg/m(2) IV on day I and etoposide 100 mg/m(2)
IV on days 1-3 on cycles one, three, five and seven and topotecan 1.5
mg/m(2) IV on days 1-5 on cycles two, four, six and eight. Cycles were
repeated every 21 days. Patients’ median age was 60 years and
performance status (WHO) was 0 for 13, 1 for 20 and 2 for three
patients. All patients were evaluable for response and toxicity.
Results: Five (14%) patients achieved a complete response and 18 (50%)
a partial response for an overall response rate of 64% (95% confidence
interval: 48.2-79.6%). After a median follow up of 10 months, the
median duration of response was 5.5 months, the time to tumor
progression 8 months and the probability of 1-year survival 48.9%. A
total of 126 cycles of cisplatin-etoposide and 117 cycles of topotecan
were administered with a median number of 4 cycles/patient for each
regimen. There were no toxic deaths. Treatment delays due to toxicity
occurred in 13 (10%) cycles after cisplatin-etoposide and 16 (14%)
cycles after topotecan while doses were reduced in seven (6%) and five
(4%) cycles, respectively. Grade 3-4 neutropenia, thrombocytopenia and
febrile neutropenia complicated 13, 1 and 3% of cisplatin-etoposide
cycles and 28, 6 and 1% of topotecan, respectively. Non-hematologic
toxicity was mild. The delivered dose intensity was 96% for cisplatin
and etoposide and 98% for topotecan. Conclusions: The alternating
administration of cisplatin-etoposide and topotecan is a feasible,
active and well-tolerated regimen in patients with extensive stage SCLC.
(C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
Συγγραφείς:
Mavroudis, D
Veslemes, M
Kouroussis, C
Tzanakis, N and
Ferdoutsis, E
Toumbis, M
Ziotopoulos, P
Agelidou, M and
Tselepatiotis, E
Kalbakis, K
Souglakos, J
Magkanas, E and
Samonis, G
Georgoulias, V
Hellenic Oncology Res Grp
Εκδότης:
ELSEVIER SCI IRELAND LTD
Λέξεις-κλειδιά:
small cell lung cancer; cisplatin; etoposide; topotecan; alternating
DOI:
10.1016/S0169-5002(02)00149-6
